February 2016 Special Edition
Volume 2, Issue 2.1
This supplement features updated information on late-breaking drug approvals for bleeding disorders, leukemia, and myeloma.
Table of Contents
Hematology Pipeline Update 2016
ASH/FDA Joint Symposium on Late-Breaking Drug Approvals: Looking into the Future of Myeloma Treatment
At the 2015 ASH Annual Meeting, the U.S. Food and Drug Administration (FDA) sponsored a session reviewing drugs that received FDA approval in November...
How Should Clinicians Be Using Newly Approved Drugs in Practice?
In 2015, the U.S. Food and Drug Administration (FDA) approved several new therapies for the treatment of hematologic disorders – ranging from the first...
Hematology Pipeline Update 2016
Panobinostat Plus Bortezomib and Dexamethasone Safe in Transplant-Eligible Myeloma Patients
The selective histone deacetylase (HDAC) inhibitor panobinostat was safe and effective when used in combination with bortezomib and dexamethasone (RVD) in patients with newly...
ABL001 Shows Signs of Overcoming TKI Resistance in Heavily Pretreated Patients with CML
The small molecule ABL001 exhibits rapid anti-tumor activity in heavily pretreated patients with chronic myeloid leukemia (CML), according to research presented by Oliver G....
New Antibody-Drug Conjugate Demonstrates Anti-Leukemic Activity in CD33-Positive AML
CD33 is expressed on myeloblasts in approximately 90 percent of acute myeloid leukemia (AML) cases – regardless of patient age, prior therapies, or mutational...
Survival Rates with Clofarabine Inferior to Standard Therapy in Older Patients with AML
Despite demonstrating clinical activity in older patients with newly diagnosed acute myeloid leukemia (AML) in phase II studies, single-agent clofarabine failed to produce similar...
Hematology Pipeline Update 2016
Combo of Ixazomib, Lenalidomide, Dexamethasone Leads to Longer PFS in Relapsed/Refractory Multiple Myeloma
The triplet combination of the oral proteasome inhibitor (PI) ixazomib and the immunomodulatory drugs lenalidomide and dexamethasone resulted in longer progression-free survival (PFS) than...
Daratumumab Combination Produces Durable Responses in Patients with RRMM
The anti-CD38 monoclonal antibody daratumumab produces durable responses when used in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM), according...
Hematology Pipeline Update 2016
Targeting Antithrombin: The Key to Achieving Hemostatic Balance in Hemophilia Patients?
Targeting the endogenous anticoagulant antithrombin (AT) in patients with hemophilia restored hemostatic balance and prevented severe bleeding in people with severe forms of the...
